全文获取类型
收费全文 | 4402811篇 |
免费 | 383888篇 |
国内免费 | 16287篇 |
专业分类
耳鼻咽喉 | 62945篇 |
儿科学 | 136919篇 |
妇产科学 | 114665篇 |
基础医学 | 676217篇 |
口腔科学 | 123154篇 |
临床医学 | 403247篇 |
内科学 | 802551篇 |
皮肤病学 | 109239篇 |
神经病学 | 378805篇 |
特种医学 | 176226篇 |
外国民族医学 | 912篇 |
外科学 | 670859篇 |
综合类 | 127563篇 |
现状与发展 | 28篇 |
一般理论 | 2649篇 |
预防医学 | 370066篇 |
眼科学 | 104237篇 |
药学 | 313983篇 |
24篇 | |
中国医学 | 13329篇 |
肿瘤学 | 215368篇 |
出版年
2021年 | 59550篇 |
2020年 | 39506篇 |
2019年 | 65670篇 |
2018年 | 79819篇 |
2017年 | 62368篇 |
2016年 | 69649篇 |
2015年 | 83962篇 |
2014年 | 119265篇 |
2013年 | 185471篇 |
2012年 | 128581篇 |
2011年 | 131423篇 |
2010年 | 131133篇 |
2009年 | 132033篇 |
2008年 | 115511篇 |
2007年 | 121553篇 |
2006年 | 130240篇 |
2005年 | 125087篇 |
2004年 | 125138篇 |
2003年 | 115167篇 |
2002年 | 105273篇 |
2001年 | 156197篇 |
2000年 | 152180篇 |
1999年 | 140875篇 |
1998年 | 71758篇 |
1997年 | 68117篇 |
1996年 | 65939篇 |
1995年 | 61775篇 |
1994年 | 55827篇 |
1993年 | 51781篇 |
1992年 | 104202篇 |
1991年 | 99574篇 |
1990年 | 94616篇 |
1989年 | 92213篇 |
1988年 | 85786篇 |
1987年 | 84226篇 |
1986年 | 79918篇 |
1985年 | 78275篇 |
1984年 | 66183篇 |
1983年 | 59071篇 |
1982年 | 48245篇 |
1981年 | 44965篇 |
1980年 | 42260篇 |
1979年 | 58047篇 |
1978年 | 47173篇 |
1977年 | 41742篇 |
1976年 | 38801篇 |
1975年 | 37957篇 |
1974年 | 42575篇 |
1973年 | 40698篇 |
1972年 | 38160篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献992.
Miju Bae Sung Woon Chung Chung Won Lee Up Huh Min Su Kim Seung Hwan Song 《Asian journal of surgery / Asian Surgical Association》2019,42(1):235-239
Background
In Leriche syndrome, postoperative graft thrombosis remains one of the most significant clinical challenges.Methods
We reviewed 51 patients who underwent surgery for aortoiliac occlusive disease at our hospital from January 2007 to December 2014. The factors associated with graft patency were determined using the Cox proportional hazard model.Results
The 2-year prosthetic graft patency rate was 72.5%. Younger age (p = 0.017, Odd ratio (OR) = 1.112), postoperative uncontrolled hypertension (p = 0.044, OR = 3.797), and associated Trans Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease II (TASC II) D femoropopliteal lesion (p = 0.008, OR = 11.139) were significantly related factors for prosthetic graft patency after surgical repair. The existing comorbidities of the patients that indicated the need for axillo-bifemoral bypass seemed to be related to lower graft patency or other complications.Conclusions
For better graft patency after an open surgical repair of Leriche syndrome, strict postoperative hypertension control and distal run-off resolution are necessary. 相似文献993.
Oga Emmanuel. A. Peters Erica. N. Mark Katrina Trocin Kathleen Coleman-Cowger Victoria. H. 《Maternal and child health journal》2019,23(2):250-257
Maternal and Child Health Journal - Background Prenatal substance use screening is recommended. The 4 P’s Plus screener includes questions on perceived problematic substance use in parents... 相似文献
994.
995.
996.
Sharisse M. Arnold Rehring Liza M. Reifler Jennifer H. Seidel Karen A. Glenn John F. Steiner 《Academic pediatrics》2019,19(5):572-580
ObjectiveClinical specialty societies recommend long-acting reversible contraceptives (LARCs) as first-line contraception for adolescent women. We evaluated whether a combined educational and process improvement intervention enhanced LARC placement in primary care within an integrated health care system.MethodsThe intervention included journal clubs, live continuing education, point-of-care guidelines, and new patient materials. We conducted a retrospective cohort study across 3 time periods: baseline (January 2013?September 2015), early implementation (October 2015–March 2016), and full implementation (April 2016–June 2017). The primary outcome was the proportion of LARCs placed by primary care clinicians among women aged 13 to 18 years compared with gynecology clinicians.ResultsKaiser Foundation Health Plan of Colorado cared for approximately 20,000 women aged 13 to 18 years in each calendar quarter between 2013 and 2017. Overall, LARC placement increased from 7.0 per 1000 members per quarter at baseline to 13.0 per 1000 during the full intervention. Primary care clinicians placed 6.2% of all LARCs in 2013, increasing to 32.1% by 2017 (P < .001), including 45.5% of contraceptive implants. Clinicians who attended educational sessions were more likely to adopt LARCs than those who did not (17.9% vs 6.4% respectively, P = .009). Neither overall LARC placement rates (relative risk, 1.9; 95% confidence interval, 0.7?5.6) nor contraceptive implant rates (relative risk, 3.0; 95% confidence interval, 0.9?9.8) increased significantly in clinicians who attended educational activities.ConclusionsThis multimodal intervention was associated with increased LARC placement for adolescent women in primary care. The combination of education and process improvement is a promising strategy to promote clinician behavior change. 相似文献
997.
998.
999.
1000.